Acadia: DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

 Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.

https://www.biospace.com/article/releases/acadia-pharmaceuticals-announces-daybue-trofinetide-is-now-available-for-the-treatment-of-rett-syndrome/